Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Laromestrocel (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Registrational; Therapeutic Use
- Acronyms ELPIS II; ELPISII
- Sponsors Longeveron
Most Recent Events
- 25 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2025 Planned number of patients changed from 38 to 40.
- 19 Jun 2025 Planned End Date changed from 31 Aug 2025 to 31 Aug 2026.